The role of academia and the research community in assisting the food and drug administration to ensure U.S. drug safety
- 16 April 2007
- journal article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 16 (7) , 818-825
- https://doi.org/10.1002/pds.1398
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Estimating The Cost Of New Drug Development: Is It Really $802 Million?Health Affairs, 2006
- Reform of Drug Regulation — Beyond an Independent Drug-Safety BoardNew England Journal of Medicine, 2006
- Financial Conflicts of Interest and the Food and Drug Administration's Advisory CommitteesNew England Journal of Medicine, 2005
- Postmarketing Surveillance—Lack of Vigilance, Lack of TrustJAMA, 2004
- Failing the Public Health — Rofecoxib, Merck, and the FDANew England Journal of Medicine, 2004
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Timing of New Black Box Warnings and Withdrawals for Prescription MedicationsJAMA, 2002
- Promotion of Prescription Drugs to ConsumersNew England Journal of Medicine, 2002
- Making Medicines Safer — The Need for an Independent Drug Safety BoardNew England Journal of Medicine, 1998
- The US Food and Drug Administration Modernization Act of 1997: impact on consumersClinical Therapeutics, 1998